SAN DIEGO, May 13 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA - News) today announced the pricing of its initial public offering of 6,500,000 shares of common stock at a price of $11.00 per share. All of the shares are being offered by NuVasive. NuVasive also granted to the underwriters a thirty-day option to purchase up to an additional 975,000 shares of common stock to cover over allotments, if any. The shares will be listed on The NASDAQ Stock Market under the symbol "NUVA."
Banc of America Securities LLC and Lehman Brothers are acting as joint book-running managers, and Thomas Weisel Partners LLC and William Blair & Company are acting as co-managers.
The public offering is being made only by means of a prospectus. Copies of the final prospectus relating to the offering can be obtained from either Banc of America Securities LLC, c/o Prospectus Department, 100 West 33rd Street, New York, NY 10001 (phone (646) 733-4166), or from Lehman Brothers, c/o ADP Financial Services, Integrated Distribution Services, 1155 Long Island Avenue, Edgewood, NY 11717 (phone (631) 254-7106, fax (631) 254-72680.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on May 12, 2004. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
NuVasive is a medical device company focusing on the design, development and marketing of products for use in minimally disruptive surgical treatments for the spine. NuVasive's Maximum Access Surgery (MAS) product platform includes the NeuroVision(TM) nerve avoidance system, MaXcess spine access system, and specialized implants. NuVasive also offers classic fusion implant products for use in spine surgery.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:
Statements in this press release regarding NuVasive, Inc.'s business which are not historical facts are "forward-looking statements" that involve risks and uncertainties. For example, the timing of the closing of this offering could vary based upon the timing of the satisfaction of the closing conditions contained in the underwriting agreement relating to the offering. Actual results, performance or achievements could differ materially from the Company's current expectations. NuVasive undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.
For further information, please contact: Kevin C. O'Boyle of NuVasive, Inc., +1-858-271-7070, email@example.com; or Kathy Witz Sweeney of Mentus, +1-858-455-5500, x212, firstname.lastname@example.org, for NuVasive, Inc.
Source: NuVasive, Inc.